University Challenge 2013–14

OM1 and Medtronic Partner on Propel Study to Assess Long-term Outcomes for Patients With Chronic Rhinosinusitis

Retrieved on: 
Tuesday, April 9, 2024
Data Management, Technology, Other Health, Health, General Health, Pharmaceutical, Health Technology, Research, Artificial Intelligence, Surgery, Science, University Challenge 2013–14, Partnership, Physician, Inflammation, Patient, American Academy, Standard of care, CRS, AI, Medtronic, PROPEL, ENT, Sinusitis, ESS, Adhesion, Pharmaceutical industry

The study focused on healthcare resource use (HCRU) and long-term outcomes in patients with chronic rhinosinusitis (CRS) who underwent endoscopic sinus surgery (ESS).

Key Points: 
  • The study focused on healthcare resource use (HCRU) and long-term outcomes in patients with chronic rhinosinusitis (CRS) who underwent endoscopic sinus surgery (ESS).
  • The study found that PROPEL devices are associated with lower HCRU and revision surgery during a 24-month follow-up period after ESS.
  • Thus, the use of PROPEL devices may lead to payer savings from reduced healthcare resource utilization.
  • “The results of this study demonstrate a rare win-win-win within healthcare,” said Amy Van Sach, president of Medtronic ENT.

As interest rates surge: flighty deposits and lending

Retrieved on: 
Friday, April 5, 2024
Neumark, Face, BCBS, Quarterly Journal of Economics, COVID-19, Cash, MRO, Intensive word form, Duration, Disclosure, The, Return, Bank statement, DFR, Research Papers in Economics, Investment, DEP, Federal, Prudential, CEMFI, Core, Synthetic control method, Interest rate risk, Journal of Political Economy, Policy, OLS, Logic, PDF, LOAN, ECB, Risk, International, Shock, Quarterly Journal, ROA, Risk management, Panetta, HHS, T2, T3, E51, Silicon Valley Bank, Common, Social science, NBER, EBA, Propensity score matching, Control, JEL, University Challenge 2013–14, Database, Rigidity, Yb, Social Science Research Network, The Journal of Finance, Bednarek, Journal, Research, Public policy, AT1, Journal of Monetary Economics, PSM, Big data, McPhail, Literature, Medical classification, Federal Reserve, Robustness, Paper, NPL, Financial economics, Deposit account, European Central Bank, Gérard Schivardi, Remuneration, Central bank, Conference, Environment, Political economy, MDA, Equation, Collateral damage, Monetary economics, Monetary policy, Kernel, Hoffmann, Website, Movement, Reproduction, Financial intermediary, Silicon, FE, Working paper, Injection, American Economic Review, Data, G21, AnaCredit, Probability, Total, Lombard, Bank
Key Points: 

    The impact of regulatory changes on rating behaviour

    Retrieved on: 
    Tuesday, April 2, 2024
    Długosz, Disagreement, Pi bond, Direct lending, Key, Research Papers in Economics, Finance Secretary (India), University of Oxford, STS, Journal of Economic Perspectives, International, American Economic Review, Life, Columbia Business School, British Academy of Management, Risk assessment, ABS, Rating, EBA, Development, Reputational damage, OBS, CRA, Bond credit rating, Cras, Journal of Monetary Economics, CDO, Becker, Paper, 2007–2008 financial crisis, Raja, University, Environment, Journal of Financial Economics, Perception, H3, Website, Securitization, Working paper, Market, Collection, Total, European Banking Authority, Quarterly Journal of Economics, BBB, Whetten, Column, ESMA, European Journal, Issuer, Asset quality, Information revolution, Federal Reserve Bank, OLS, Statistics, PDF, Private, ECB, Surety, Weighted-average life, CCC, European Commission, Social science, Journal of Financial Stability, JEL, Real, Bias, Journal, Research, Classification, Certification, Commission, Credit, The Journal of Finance, Literature, Karel Škréta, European Central Bank, AA, Finance Research Letters, Origination (telephony), Monetary economics, Section 5, Xia, Kraft Foods, Government, AAA, Mukherjee, Finance, Deku, DOI, White, Risk, IOSCO, MBS, OECD, Wang, Section 4, University Challenge 2013–14, Section 3, Ashcraft, Financial management, Accounting, Financial economics, Fannie Mae, Conference, Pressure, Central bank, Griffin, University of Michigan, Systematic review, EPRS, Freddie Mac, Loan, BCBS, Palgrave Macmillan, R2, Microeconomics, Quarterly Journal, Financial statement analysis, The Japanese Economic Review, Christian Social Union (UK), Green, University of Huddersfield, PSM, Management, Security (finance), Security, Civil service commission, Private placement, American Economic Journal, GFC, Reproduction, IMF, Small business, Trustee, Data

    Abstract

    Key Points: 
      • Abstract
        We examine rating behaviour after the introduction of new regulations regarding Credit Rating
        Agencies (CRAs) in the European securitisation market.
      • There is empirical evidence of rating catering in the securitisation market in the pre-GFC period (He et al.,
        2012; Efing and Hau, 2015).
      • Competition among
        CRAs could diminish ratings quality (Golan, Parlour, and Rajan, 2011) and promotes rating shopping by
        issuers resulting in rating inflation (Bolton et al., 2012).
      • This paper investigates the impact of the post-GFC regulatory changes in the European
        securitisation market.
      • In 2011, in addition to the creation of
        European Securities and Markets Authority (ESMA), a regulatory and supervisory body for CRAs was
        introduced.
      • We examine how rating behaviours have changed in the European securitisation market after the
        introduction of these new regulations.
      • We utilise the existence of multiple ratings and rating agreements between
        CRAs to identify the existence of rating shopping and rating catering, respectively (Griffin et al., 2013; He
        et al., 2012; 2016).
      • We find that the regulatory changes have been effective in tackling conflicts of interest between issuers
        and CRAs in the structured finance market.
      • Rating catering, which is a direct consequence of issuer and
        CRA collusion, seems to have disappeared after the introduction of these regulations.
      • There is empirical evidence of rating catering in the securitisation market in
        the pre-GFC period (He et al., 2012; Efing and Hau, 2015).
      • Competition among CRAs could diminish ratings quality (Golan, Parlour,
        and Rajan, 2011) and promotes rating shopping by issuers resulting in rating inflation (Bolton et
        al., 2012).
      • This paper investigates the impact of the post-GFC regulatory changes in the European
        securitisation market.
      • In 2011, in addition
        to the creation of European Securities and Markets Authority (ESMA), a regulatory and
        supervisory body for CRAs was introduced.
      • We find that the regulatory changes have been effective in tackling conflicts of interest
        between issuers and CRAs in the structured finance market.
      • Rating catering, which is a direct
        consequence of issuer and CRA collusion, seems to have disappeared after the introduction of
        these regulations.
      • Investors who previously demanded higher spreads for rating agreements for a
        multiple rated tranche, did not consider the effect of rating harmony as a risk in the post-GFC
        period.
      • Regarding rating shopping, we find that the effectiveness of the changes has been limited,
        potentially for two reasons.
      • Additionally, we also find that rating over-reliance might still be an issue, especially
        Rating catering is a broad term and it can involve rating shopping.
      • They re-examine the rating shopping and rating
        catering phenomena in the US market by looking at the post-crisis period between 2009 and 2013.
      • Using 622 CDO tranches, they also observe the existence of rating shopping and the diminishing
        of the rating catering.
      • Firstly, our main focus is the EU?s CRA Regulation and its effectiveness in reducing
        rating inflation and rating over-reliance.
      • To the best of our knowledge, this paper is the first to
        examine the effectiveness of the EU?s CRA regulatory changes on the investors? perception of
        rating inflation in the European ABS market.
      • Hence, the coverage and quality of our dataset constitutes significant addition
        to the literature and allows us to test the rating shopping and rating catering more authoritatively.
      • The following section reviews the literature
        on securitisation concerning CRAs and conflicts of interest, and outlines the regulatory changes
        introduced in the post-GFC period.
      • Firstly, ratings became ever more important as the Securities and
        Exchange Commission (SEC) 5 began heavily relying on CRA assessments for regulatory purposes
        (i.e.
      • the investment mandates that highlight rating agencies as the main benchmark for investment
        eligibility) (SEC, 2008; Kisgen and Strahan, 2010; Bolton et al., 2012).
      • issuers) as one of the main explanations for the rating inflation (He et al., 2011; 2012; Bolton
        et al., 2012; Efing and Hau, 2015).
      • Bolton et al., (2012) demonstrate that competition
        promotes rating shopping by issuers, leading to rating inflation.
      • The last phase, CRA III, was implemented in mid-2013 and involves an additional
        set of measures on reducing transparency and rating over-reliance.
      • As mentioned above, rating inflation can be caused by rating shopping
        In order to be eligible to use the STS classification, main parties (i.e.
      • The higher the difference in the number of ratings for a
        given ABS tranche, the greater the risk of rating shopping.
      • Alternatively, the impact of the new
        regulations could be limited when it comes to reducing rating shopping.
      • This is because, firstly,
        the conflict of interest between securitisation parties is not necessarily the sole cause for the
        occurrence of rating shopping.
      • L is a set of variables (Multiple ratings, CRA reported, Rating agreement) that
        we utilise interchangeably to capture the rating shopping and rating catering behaviour.
      • Hence, issuers are incentivised to report the highest possible rating and
        ensure each additional rating matches the desired level.
      • All in all, our results suggest that
        the new stricter regulatory measures have been effective in tackling conflicts of interest and
        reducing rating inflation caused by rating catering.
      • Self-selection might be a concern in analysing the impact of the
        new measures and investors? response with regard to the rating inflation.
      • This
        result is in line with the earlier findings suggesting that regulatory changes have reduced investors?
        suspicion of rating inflation and increased trust of CRAs.
      • Conclusion
        Several regulatory changes were introduced in Europe following the GFC aimed at tackling
        conflicts of interest between issuers and CRAs in the ABS market.
      • Utilising a sample of 12,469
        ABS issued between 1998 and 2018 in the European market, this paper examined whether these
        changes have had any impact on rating inflations caused by rating shopping and rating catering
        phenomena.
      • We find that the
        effectiveness of the changes has been more limited on rating shopping potentially for two reasons.
      • Tranche Credit Rating is the rating reported for a tranche at launch.

    3Spine Announces Completion of FDA Clinical Trial Enrollment Achieving 325 Surgeries in 2023

    Retrieved on: 
    Wednesday, January 10, 2024
    Titanium, IDE, Spinal fusion, Patient, Research, Principal, Cobalt-chrome, Learning, University Challenge 2013–14, Laminectomy, Friends, Rotation, Medicine, American Medical Association, Back pain, NYU, CPT, Synovial joint, FDA, Clinical trial, Decompression, Contra, Pharmaceutical industry

    The company enrolled a larger fusion cohort in an adaptive statistical design to improve propensity score matching between data sets.

    Key Points: 
    • The company enrolled a larger fusion cohort in an adaptive statistical design to improve propensity score matching between data sets.
    • The trials involved patients experiencing chronic leg and back pain ranging in age from 23 to 79 across 14 U.S. states.
    • 3Spine plans to seek FDA approval through the Premarket Approval pathway.
    • Information on the real-world fusion clinical trial is available at NCT04823858 .

    Largest real-world study finds tirzepatide (Mounjaro) up to three times more effective than semaglutide (Ozempic) for weight loss

    Retrieved on: 
    Monday, November 27, 2023
    EHR, Providence Portland Medical Center, SDOH, Semaglutide, Overweight, Physician, FDA, Weight loss, Paper, FACC, Health, MD, Doctor of Philosophy, Education, Prescription, University Challenge 2013–14, MHA, Type 2 diabetes, Obesity, FAHA, CARDS, Patient, Human, Data science, Infection, Female, GIP, Pharmaceutical industry

    In this study, Truveta Research explored weight loss trends for patients taking semaglutide and tirzepatide approved by the FDA for treating type 2 diabetes (Ozempic and Mounjaro, respectively).

    Key Points: 
    • In this study, Truveta Research explored weight loss trends for patients taking semaglutide and tirzepatide approved by the FDA for treating type 2 diabetes (Ozempic and Mounjaro, respectively).
    • The study found that in the initial unadjusted population, those taking tirzepatide and semaglutide differed.
    • The analysis found that patients taking tirzepatide were significantly more likely to achieve weight loss:
      Those taking tirzepatide were 1.8 times more likely than those taking semaglutide to achieve 5% weight loss,
      2.6 times more likely than those taking semaglutide to achieve 10% weight loss,
      And three times more likely than those taking semaglutide to achieve 15% weight loss.
    • At six months, the mean percentage change in body weight was -10.1% for those taking tirzepatide versus -5.9% for those taking semaglutide.

    Mitsubishi Tanabe Pharma America Showcases Depth of ALS Research with Wide Range of Abstracts at 22nd Annual NEALS Meeting

    Retrieved on: 
    Wednesday, October 4, 2023
    Real-World Evidence, Medical Affairs Bureau, Mitsubishi Tanabe Pharma, MGH, IDMC, MND, ALS, Research, NCRI, Mitsubishi Group, Biomarker, Data mart, Intravenous therapy, MTPA, CDM, Netherlands Institute for Sound and Vision, NHC, Survival, University Challenge 2013–14, Hospital, Patient, SVC, FDA, Massachusetts General Hospital, Disease, Pharmaceutical industry, Nursing, Edaravone, Safety, Optum

    JERSEY CITY, N.J., Oct. 4, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that eight presentations in amyotrophic lateral sclerosis (ALS) will be shared at the 22nd Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting, being held in Clearwater, Fla., from October 4-6.

    Key Points: 
    • JERSEY CITY, N.J., Oct. 4, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that eight presentations in amyotrophic lateral sclerosis (ALS) will be shared at the 22nd Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting, being held in Clearwater, Fla., from October 4-6.
    • Presentations include:
      A preliminary analysis of demographics and clinical characteristics in people with ALS being treated with RADICAVA ORS, utilizing U.S.-based administrative claims data from Optum's Clinformatics® Data Mart (CDM), will be presented.
    • REFINE-ALS is a NEALS-affiliated clinical trial sponsored by MTPA and conducted in collaboration with the Neurological Clinical Research Institute (NCRI) at Massachusetts General Hospital (MGH).
    • Real-World Survival Effectiveness of Edaravone in Amyotrophic Lateral Sclerosis: A Propensity Score Weighted, Registry-based, Canada-wide Cohort Study
      Real-World Evidence on Treatment Retention, Safety, and Tolerability of Edaravone in Canadian Patients With Amyotrophic Lateral Sclerosis

    Pelago Achieves Healthcare Cost Savings of $9,367 (3x ROI) in First Ever Substance Use Management Medical Claims Analysis

    Retrieved on: 
    Thursday, August 17, 2023
    Presenteeism, Sherwani, Pancreatitis, Medicine, Obesity, Depression, Suds, Liver disease, University Challenge 2013–14, Anxiety, Parent, Overalls, Absenteeism, Cardiovascular disease, Risk management, Research, Centers for Disease Control and Prevention, Tobacco, Wilcoxon, Substance, CDC, Randomized controlled trial, SUD, Adolescence, Ageing, ROI, Smoking, Mental health, Pharmaceutical industry, Pelago

    NEW YORK, Aug. 17, 2023 /PRNewswire/ -- Pelago (formerly Quit Genius), the leading digital clinic partner to U.S. businesses and health plans for substance use management, today announced results of its substance use disorder (SUD) claims analysis. The analysis demonstrated that Pelago reduced medical claims on an annual basis by $9,367 per participant compared to a control group, delivering a 3.0x ROI. The study's methodology, assumptions, savings, feasibility, and credibility were independently reviewed by a global leader in risk management.

    Key Points: 
    • The analysis demonstrated that Pelago reduced medical claims on an annual basis by $9,367 per participant compared to a control group, delivering a 3.0x ROI.
    • The study's methodology, assumptions, savings, feasibility, and credibility were independently reviewed by a global leader in risk management.
    • Medical claims of Pelago members with tobacco and alcohol use disorders were compared to a matched control group comprising nonparticipants in the Pelago programs with diagnoses of tobacco and alcohol use disorders in 2022.
    • "We've been able to confidently estimate and establish the impact of our substance use management program on overall healthcare costs and to identify the main drivers of overall cost savings."

    Study Data from Castle Biosciences’ Collaboration with the National Cancer Institute’s SEER Program Registries Published in JCO Precision Oncology

    Retrieved on: 
    Friday, June 30, 2023
    Oncology, Health, Genetics, Other Health, Research, Science, Biotechnology, Registry, University Challenge 2013–14, Public, Overalls, Survival, Cohort (statistics), Risk, JCO, American Joint Committee on Cancer, Patient, CM, Melanoma, SEER, Mortality, Lymph node, NCI, Metastasis, Medical imaging, Pharmaceutical industry

    Additionally, data from the study shows that testing with DecisionDx-Melanoma was associated with lower melanoma-specific and overall mortality relative to untested patients.

    Key Points: 
    • Additionally, data from the study shows that testing with DecisionDx-Melanoma was associated with lower melanoma-specific and overall mortality relative to untested patients.
    • This large study of real-world, unselected, clinically tested patients who received our test as part of their ongoing melanoma care further supports these findings.
    • Key findings of the study include:
      DecisionDx-Melanoma independently risk-stratified patients according to their risk of dying from melanoma, consistent with previously published retrospective and prospective studies.
    • “We are looking forward to continuing our collaboration with the NCI SEER Program’s Registries to provide DecisionDx Melanoma data to the SEER registries as part of public health reporting to further advance research and patient care.”

    Newly Published Data Demonstrates Positive Outcomes Resulting from Pathnostics' Advanced Urinary Tract Infection (UTI) Test

    Retrieved on: 
    Tuesday, June 20, 2023
    Diabetes, Urinary tract infection, UTI, University Challenge 2013–14, ABR, Cutis marmorata telangiectatica congenita, Number needed to treat, Drug resistance, Infection and Drug Resistance, SUC, Utilization, Antimicrobial resistance, Diagnosis, Medicare Part D, Health, Medical imaging, Nursing, Pharmaceutical industry, Hospital, Patient

    IRVINE, Calif., June 20, 2023 /PRNewswire/ -- Pathnostics, a leading precision diagnostic testing and development company, today announced the publication of two new studies demonstrating positive outcomes resulting from its advanced urinary tract infection (UTI) test. The studies show that treatment based on the company's Guidance® UTI test resulted in decreased health care resource utilization and costs compared to standard urine culture (SUC) tests, as well as reduced antibiotic resistance in patients with complicated urinary tract infections.

    Key Points: 
    • In fact, average one-year costs related to UTIs were $501.85 lower for patients receiving treatment based on the Guidance® test than for those based on the traditional culture test.
    • In addition, results showed patients diagnosed via the Guidance® test had improved outcomes, including fewer inpatient episodes and lower inpatient costs.
    • Separately, data published in the peer-reviewed journal Infection and Drug Resistance suggests that treatment based upon Guidance® UTI testing resulted in reduced antibiotic resistance in symptomatic patients with suspected complicated UTIs.
    • "These new findings, combined with ongoing studies, support our mission of increasing access to advanced UTI testing that supports more informed treatment leading to improved outcomes."

    Real-World Data Presented by Evoke Pharma and EVERSANA at Digestive Disease Week 2023 Shows Gimoti® Meaningfully Reduces Utilization of Healthcare Resources

    Retrieved on: 
    Tuesday, May 9, 2023
    Gastroparesis, Insurance, Hospital, University Challenge 2013–14, UC San Diego Health, Absorption, Abdominal pain, Associate, Index, Vomiting, DDW, NCMP, Patient, Physician, DGP, Nausea, Bloating, Metoclopramide, ED, GI, Female, NMCP, Pharmaceutical industry

    HCRU is the description and quantification of patients’ total usage of healthcare services such as hospitalization or how often they visit their physician in office.

    Key Points: 
    • HCRU is the description and quantification of patients’ total usage of healthcare services such as hospitalization or how often they visit their physician in office.
    • Similarly, for inpatient hospitalizations and emergency department visits the likelihood was 68% and 60% lower, respectively, for NMCP-treated patients versus OMCP.
    • The positive effects of nasal metoclopramide versus oral metoclopramide on patients and healthcare resources is worth noting and encouraging for the GI motility community.
    • We strongly believe GIMOTI has the potential to be the standard of care for DGP treatment,” commented Matt D’Onofrio, President and COO of Evoke Pharma.